EGFR and non-small cell lung carcinoma: The ABC clinical trial of the combination of afatinib and bevacizumab after acquired resistance to EGFR–TKI in EGFR‐mutant NSCLC exhibited a median PFS of 6.3 months (95% CI: 3.9–8.7 months).11